February 25, 2004 09:04 AM EST

Indevus Initiates Phase I Clinical Trial of Aminocandin for Systemic Fungal Infections

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 25, 2004--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced the initiation of a Phase I clinical trial with aminocandin, a member of a new class of anti-fungal compounds under development for the treatment of a broad spectrum of systemic, invasive infections. This trial will test the safety and tolerability of escalating single doses of aminocandin administered intravenously in healthy volunteers. Results of the trial are expected in the second half of 2004.